DOCK2 has been identified to be associated with prognostic factors in a variety of cancer types, such as acute myeloid leukemia, prostate cancer, colorectal cancer, and non-small cell lung cancer, indicating that DOCK2 is a promising therapeutic target. This evidence concerns the gene DOCK2 and prostate carcinoma.